159 related articles for article (PubMed ID: 8195034)
21. Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake.
Skarsgard LD; Acheson DK; Vinczan A; Wouters BG; Heinrichs BE; Loblaw DA; Minchinton AI; Chaplin DJ
Br J Cancer; 1995 Dec; 72(6):1479-86. PubMed ID: 8519663
[TBL] [Abstract][Full Text] [Related]
22. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
[TBL] [Abstract][Full Text] [Related]
23. Bioreductive drugs: from concept to clinic.
McKeown SR; Cowen RL; Williams KJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
[TBL] [Abstract][Full Text] [Related]
24. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
Lartigau E; Stern S; Guichard M
Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
Stern S; Guichard M
Radiother Oncol; 1996 Nov; 41(2):143-9. PubMed ID: 9004358
[TBL] [Abstract][Full Text] [Related]
26. Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia.
Takeuchi H; Baba H; Maehara Y; Sugimachi K; Newman RA
Cancer Chemother Pharmacol; 1996; 38(1):1-8. PubMed ID: 8603441
[TBL] [Abstract][Full Text] [Related]
27. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of bioreductive drugs in multicell spheroids.
Durand RE; Olive PL
Int J Radiat Oncol Biol Phys; 1992; 22(4):689-92. PubMed ID: 1544838
[TBL] [Abstract][Full Text] [Related]
29. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
Olive PL
Br J Cancer; 1995 Mar; 71(3):529-36. PubMed ID: 7880735
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia and acidity increase the cytotoxicity of mitomycin C and carboquone to human tumor cells in vitro.
Kohnoe S; Emi Y; Takahashi I; Yoshida M; Maehara Y; Sugimachi K
Anticancer Res; 1991; 11(4):1401-4. PubMed ID: 1746896
[TBL] [Abstract][Full Text] [Related]
31. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Elwell JH; Siim BG; Evans JW; Brown JM
Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
[TBL] [Abstract][Full Text] [Related]
32. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
Patterson AV; Robertson N; Houlbrook S; Stephens MA; Adams GE; Harris AL; Stratford IJ; Carmichael J
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):369-72. PubMed ID: 8195035
[TBL] [Abstract][Full Text] [Related]
33. Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours.
Phillips RM; Clayton MR
Br J Cancer; 1997; 75(2):196-201. PubMed ID: 9010026
[TBL] [Abstract][Full Text] [Related]
34. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
35. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
Lartigau E; Guichard M
Int J Radiat Biol; 1995 Feb; 67(2):211-6. PubMed ID: 7884290
[TBL] [Abstract][Full Text] [Related]
36. 2-Alkylsulfonyloxy-3-hydroxy-1,4-naphthoquinones: a novel class of radio- and chemosensitizers of V79 cells.
Hatzigrigoriou E; Papadopoulou MV; Shields D; Bloomer WD
Oncol Res; 1993; 5(1):29-36. PubMed ID: 8369573
[TBL] [Abstract][Full Text] [Related]
37. Bioreductive therapies: an overview of drugs and their mechanisms of action.
Rauth AM; Melo T; Misra V
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
[TBL] [Abstract][Full Text] [Related]
38. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
Papadopoulou MV; Bloomer WD
Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
[TBL] [Abstract][Full Text] [Related]
39. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
Olive PL
Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
[TBL] [Abstract][Full Text] [Related]
40. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
